BioSpace News Archive

Genocea Biosciences, Inc. will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.

Nevro Corp., a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, announced its financial results for the first quarter ended March 31, 2020.

First Quarter 2020 Total Revenue grew 68% to $8.7M and Product Sales grew 78% to $8.2M over Q1 2019

AB680, the first small-molecule CD73 inhibitor in the clinic, continues in a Phase 1 dose-escalation combination trial for first-line treatment of pancreatic cancer, with a recommended dose for expansion anticipated to be established in mid-2020

PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the first quarter ended April 5, 2020.

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three-month period ended March 31, 2020.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced the commencement of a proposed underwritten public offering of $100 million of shares of its common stock.

ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced it will be part of EVIDENCE, a public-private consortium supported by the European Union in the framework of the EU Horizon 2020 program.

MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or “the Company”), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced the appointment of William L. Phelan as Senior Vice President and Chief Accounting Officer, effective May 1, 2020.